The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It's all about opinions and I think mine has more substance than the ramping gang.
Y
DP,
Kindly expand on your substance so we can debate it properly
Thanks
Needing cash is a certainty....a good news RNS is a remote possibility
Crikey Dick,
Based on that detailed analysis I'd better sell my 500K shares immediately. lol
Dick,
You need to look at this objectively.
It is an absolute certainty that a Scancell will need cash. What we don’t know for sure is when and how.
It is an absolute certainty that there will be a good news RNS. If you look at what Scancell have done, what they are doing now and the results it is incomprehensible that there won’t be some good news at some point. What we don’t know is when and what or whether there may be some not so good news before.
Nicely put Ruck, I think I noticed a few positives there too.
ATB
Dick, funny isn"t it that respected posters accuse this BB of not being able to debate anything, one lauds over us how superior his knowledge is, talking down to us, but nobody is minded to corret your false statements, your rudeness about rose tinted spectacles your inability to debate anything above a childs 5 year age group mentality. Does it feel good?
And..................."".a good news RNS is a remote possibility""", is that a fact too???
Yes a raising of funds is a certainty at some point, although you have no idea of the cash flow, have you ever heard of a raising where the share price rises? Like when Vulpes bought in at 5p and we rose to 9.4p, have you ny idea that we have three collaborations with Avidamab ready nearly for fruition, a possibility of some kind of deal with Biontech on the TCR Platform, COVIDITY, not over by a long way, a very impressive media blitz to promote Scancell with its proven canditate SCIB1 ready to trial with the market leader Keytruda, as soon as we can, and hopefully by this time next year the first patients injected for MOD1 trial.........................and all you can say is................"".a good news RNS is a remote possibility"""
We don"t even know yet the terms of any raising, whether a high profile Pharma could take a holding?? I must get rid of my rose tinted spectacles.
Pretty sure along with any funding news, before and after we will be able to communiate some very positive news by way of RNS, maybe do some research Dick, you sure sound like one.
Bunsie,
There are plenty of positives with Scancell. This doesn’t mean we can’t acknowledge the risks where such exist. It’s a case of being honest and realistic.
Thanks Ruck, hadn"t seen your post.
GN Guys, risk/reward, Avidamab looming very aware we could fall before we rise, but didn"t want to miss 5.5p, because nothing is a certainty. The trading range of 6p-9p which so many of us did well from (considering we are clueless, lol) I think could be replaced sooner than later. Low volume today, importantly one of the first Mondays without a fair few sells at 5.305, just maybe this could be a very good entry/top up point?? And that is AIMHO
Nowt new to research on this one.. its the same old stuff repeated time and time again.
Dick,
Sorry to hear you are so negative, perhaps you could read through some of the informative posts and perhaps also look at Scancell's website:-
24 June 2020
Scancell Holdings plc
(“Scancell” or the “Company”)
New publication highlights potential of Modi-1 for hard to treat cancers
Modi-1 Phase 1/2 trial expected to start in H1 2021
Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer,
is pleased to announce the publication of a peer-reviewed research paper in the Journal for
ImmunoTherapy of Cancer entitled: “Combination vaccine based on citrullinated vimentin and enolase
peptides induces potent CD4-mediated anti-tumor responses”.1 The Company also provides an update
on current progress and future plans for a Phase 1/2 clinical trial in patients with solid tumours including
triple negative breast cancer, ovarian cancer, renal cancer and head and neck cancer.
Scancell’s Moditope® platform represents a completely new class of potent and selective
immunotherapy agents based on stress-induced post-translational modifications (siPTM) such as
citrullination. The publication describes the first Moditope® vaccine, Modi-1, and its ability to stimulate
potent T cell responses that translate into tumour protection in melanoma and ovarian cancer models.
The responses were mediated by CD4 T cells and were also able to protect against a second challenge
of the tumour confirming the induction of a memory response. The paper also confirms that conjugating
the Modi-1 citrullinated peptides to the toll-like receptor-stimulating adjuvant AMPLIVANT®, previously
licensed from ISA Pharmaceuticals, allows the therapeutic dose to be reduced by up to 100-fold. The
full abstract is detailed below.
In January 2020, the Company provided an update on progress towards initiating the Modi-1 Phase 1/2
clinical trial. This has been advanced further with successful completion of GMP drug substance
manufacture for all three of the conjugates that comprise the Modi-1 product. Importantly, the technical
challenges reported in January concerning one of the peptide components have been successfully
resolved, enabling progression to GMP drug product manufacture and formulation of clinical supplies
in Q3 2020.
Formal regulatory-compliant toxicity studies have now been completed, with no evidence of any local
or systemic toxicities being reported. In addition to the Scientific Advice meeting held with the PaulEhrlich-Institut regulatory authority in 2019, a further successful meeting was held with the UK
Medicines and Healthcare products Regulatory Agency in February 2020. The Company continues to
progress the necessary processes and documentation required for regulatory submission to start the
planned clinical study in the UK in the first half of 2021.
Professor Lindy Durrant, Chief Scientific Officer of Scancell, commented:
“These data further validate the unique mode of action, and long-term prote
So what's exactly new?
Dick,
This last post was only from a few weeks ago from Scancell and Peer Reviewed!
Dick,
“ So what's exactly new?”
If you didn’t already know this then everything.
If you Did know it all, then nothing.
This is why it is so important to DYOR, you may unearth something new or just see something in a new light.
6 trades 90 ramps, 13 realistic posts = no current market interest
Ruck..................Bunsie,
""There are plenty of positives with Scancell. This doesn’t mean we can’t acknowledge the risks where such exist. It’s a case of being honest and realistic.""
Ruck, there are a couple of things missing there, and is my observation from reading the BB the last couple of weeks and not getting involved in a debate which IMHO revolved around 4 people.
I agree we should discuss risk where it exists, but not at the expense of rewards where they exist too. I did find it very negative constantly and very concentrated on putting Inanaco to the sword at every opportunity. Inanaco posted something earlier which I didn"t mean to provoke. There is no bad blood between us, In many ways I have learnt a lot from his insights, and where I disagree I don"t make a song and dance about it, and some of the personals took away from what was a very interesting debate IMHO.
The second thing you said to Bunsie was.............."".It’s a case of being honest and realistic."".
Totally agree, I have met many people from here who post as they are, honest, realistic and can I add very decent. But the word you missed out IMHO is BALANCED,
As Bunsie just posted................Dick,
Sorry to hear you are so negative, perhaps you could read through some of the informative posts and perhaps also look at Scancell's website:-
24 June 2020
Scancell Holdings plc
(“Scancell” or the “Company”)
New publication highlights potential of Modi-1 for hard to treat cancers
That along with the other RNS I think dated 28/6 are full of interesting information, also great news with the manufacturing of the vaccine, but I read more about Scancell not updating us than we have debating two RNSs doing exactly that!!!
Anyway, can smell something coming, lets hope it is good. GN
C7,
Fair enough I suppose.
I have to disagree about the balance point. I don’t think balance is about having equal amounts of positive and negative input. I think it is about a realistic and true amount of positive and negative.
If reality puts us in a positive light let’s run with it. No point inventing negatives for the sake of “balance”. The opposite would be true as well of course.
There you are, disagreeing again but getting along lol!
Well as Bermuda says, we agree to differ, but I seem to remember a few people saying something similar last week, but like I said I enjoyed a fair bit of that debate. I wasn"t going to replenish my trading pot but like the previous 5 trades this year I can just smell a trade whereas for years I was only interested in getting a core holding exceeding 200k which back in 2012 buying in at 41p I never thought was possible I find I look at things so differently trading just £1500 a time, and what came out from that debate was well we know the negatives, despite hearing constantly that we don"t consider them, believe me I am in no position to throw away £1500 so they are well considered, but we sometimes forget to consider what the positives are too.
We have no real idea what the next news will be, or when, but I just feel dependant on how we raise when that time comes we have enough items of good news to rise too and I do keep mentioning when Vulpes came in after hitting 3.5p when the world was caving in, there buys at 5p saw us rise to 9.4p. Unfortunately whether our fault or not the FDA were delaying approval, the coronavirus was unforeseen but we did string together 3 collaborations with Avidamab which seemed to be pretty handpicked in three different continents, the first of which reaches the 12 month period CH suggested as a timeline in just 7 weeks time, and that I think alone could dictate whatever plans the BOD have to raise, and by then we could be in a position to proceed with the combo trial, and when the other 2 mature that could well dictate when we can inject the first patient in the MOD1 trial, where so much of our faith lies. There are many other items of good news from TCRs, possibly SCIB2 as well as financing those 2 trials that unlike what dickpuller posted nothing is a certainty least of all just a 10% chance of a good RNS!!!!
Each to their own as we know, and each has their own stratagy, so it is not a case of whether we are ludicrously cheap but whether from this point we offer value and as you mention realistic, well I think 8p could be revisited on a modicumof good news, hence a decent trade. When I say I think the BB has been too negative is that there are a couple of items we could do without happening, but seriously does that take weeks of debate and months every year?? We can easily forget in such an envirement the positives that do exist, ones that might exist and new ones that we are unaware of up till now. But we don"t see signs of rushing out RNSs for the sake of it in an attempt to drive up the SP for an immenent raising do we?? And even thinking about COVIDITY well I don"t think we have heard the last of that, I do believe they will need different treatments for different folks and that is without considering second waves and mutations of the same virus.
So all is not doom and gloom which IMHO is easy to pick up on here, and for now until news only too happy to see us sit at 5.5/6. BOL all GN
I agree with you C7. I have no axe to grind with SCLP . Just want to ensure folks are aware that this is as likely to hit 4.5p as 6.5p over the next few months.
dickpullar ............""..I agree with you C7. I have no axe to grind with SCLP . Just want to ensure folks are aware that this is as likely to hit 4.5p as 6.5p over the next few months"""
Appreciate that post dick, I don"tthink anybody here is under any illusions to the battle ahead, and yes find it a bit insulting to hear some justify their comments.by making it sound like anybody who has any positivity is to be questioned in regards to their honesty and realism. I play openhands here, by hich I mean I declare my buys and my sells, rather than hearing from the same people that every trade was perfect to boost their own personal standing.
To confirm this is no certainty, far from it, but could work out favourably on a modicum of good news, and there are enough items of news to achieve that, all of them I have listed and given reasons for why we ould come out of this favourably. Unfortunately sentiment is low, corona virus has paralised so many trials throughout the industry, and I thinkmany of us have suffered in some way this year with the virus, people fighting to keep their jobs and businesses, and there is a lot of ear flying around.
Wasn"t it Warren Buffet who said something like buy when others are fearful or something like that, maybe some people have forgotten already wehave fallen by nearly half from recent highs and as was pointed out we are priced as a start up, with all the IP we have.
Anyway thanks again, I was really hoping people would come out of this far kinder, but I haven"t seen that at all, Lets hope we do come out of this stronger, get back into trials see SCIB1 In combo with Keytruda and finally get to see patients dosed in MOD1 trial. Beyond the money, these trials could be life savers for tens of thousands of people around the world, trials will collect data, data that could be life changing for any one of us, and I just feel some posts show no regard whatsoever for the work of Lindy Durrant at all. I think see and SCancell deserve better. Take care, fingers crossed and lets hope first and foremost we get lucky, not something we have been awashed with at any stage.
Happy for that to be the case for the next two years to be honest.
It gives me another £40k in an ISA to sink profits into Scancell. I'm almost at the annual limit this year.
C7,
I think he (Warren Buffet) said:
“ be fearful when others are greedy, and greedy when others are fearful.”
He said lots of great things, here’s another....
“The stock market is designed to transfer money from the active to the patient.”
LOL, I think 8 years building a 250k holding, comes under the patient, and it even took me 7 years to trade Scancell for the first time this year.
This trade as I said will be a rocky road, but boy could it have legs!!!